AVNS — Avanos Medical, Inc.

Avanos (AVNS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Results: Net sales were approximately $181 million, with adjusted diluted earnings per share (EPS) of $0.29. Adjusted EBITDA for the quarter was $28 million, and adjusted gross margin stood at 53.4%.
• Full Year 2025 Results: Total net sales reached $701 million, exceeding revised guidance. Adjusted diluted EPS for the year was $0.94, with adjusted EBITDA of $87 million and adjusted gross margin of 54.6%.
• Organic Sales Growth: For the full year, adjusted organic sales for strategic segments grew 6%, with Specialty Nutrition Systems (SNS) growing over 8% and Pain Management and Recovery (PM&R) up 2.3%.

2. Strategic Updates and Business Highlights

• Specialty Nutrition Systems: Strong performance driven by long-term and short-term enteral feeding products, with notable growth from the CORTRAK and CORGRIP 2 systems. The U.K. go-direct transition contributed positively.
• Pain Management and Recovery: The radiofrequency ablation (RFA) business achieved double-digit growth, while surgical pain products faced challenges due to slower-than-expected reimbursement implementation from the NOPAIN Act.
• Portfolio Management: Successful divestitures of the hyaluronic acid business and the rental portion of GAME READY, alongside the acquisition of Nexus Medical, which is performing better than expected.

3. Forward Guidance and Outlook

• 2026 Guidance: Expected net sales between $700 million and $720 million, with mid- to high single-digit organic growth in SNS and low to mid-single-digit growth in PM&R. Adjusted diluted EPS is projected to be between $0.90 and $1.10.
• Tariff Impact: Anticipated tariff costs of approximately $30 million in 2026, primarily related to products sourced from China. The company expects to complete its exit from China by June 2026, which is expected to alleviate some tariff pressures in the second half of the year.

4. Bad News, Challenges, or Points of Concern

• Tariff Pressures: The ongoing impact of tariffs continues to obscure profitability, with a projected increase in tariff-related costs for 2026. The company is actively working on mitigation strategies, but uncertainty remains due to potential changes in trade policy.
• Surgical Pain Business: Revenue declined year-over-year due to delays in the implementation of the NOPAIN Act, which could affect future growth in this segment.
• Corporate and Other Segment Decline: The hyaluronic acid and IV therapy product lines reported a significant decline, primarily due to divestitures, which could impact overall revenue figures.

5. Notable Q&A Insights

• Tariff Mitigation: Management provided clarity on the tariff situation, indicating that about two-thirds of the projected $30 million tariff impact in 2026 is related to China. They remain confident in their mitigation strategies and the transition to production in Mexico.
• Revenue Growth Projections: Analysts inquired about organic growth rates, with management indicating a consolidated organic growth rate of around 5%, with specific segment growth rates provided.
• Operating Efficiency: Management expressed confidence in continuing to drive operating efficiencies, with plans for both internal and outsourced R&D initiatives to enhance product development and cost management.

Overall, Avanos reported solid financial performance in 2025, driven by strategic initiatives in their Specialty Nutrition Systems and Pain Management segments, while also navigating challenges related to tariffs and certain product lines. The outlook for 2026 remains cautiously optimistic, with expectations for continued growth and improved profitability.